OSE Immunotherapeutics Overview

  • Founded
  • 2004

Founded
  • Status
  • Public

  • Employees
  • 61

Employees
  • Stock Symbol
  • OSE

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $7.52

  • (As of Friday Closing)

OSE Immunotherapeutics General Information

Description

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 22, Boulevard Benoni Goullin
  • 44200 Nantes
  • France
+33 02 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OSE Immunotherapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.52 $7.56 $4.55 - $12.53 $138M 18.4M 30.4K -$0.45

OSE Immunotherapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 122,447 208,369 155,288 39,613
Revenue 37,588 31,102 11,876 29,052
EBITDA (3,021) (16,229) (20,809) (975)
Net Income (8,267) (19,922) (18,871) (5,208)
Total Assets 106,826 115,346 119,274 99,620
Total Debt 37,367 42,044 24,002 12,865
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OSE Immunotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OSE Immunotherapeutics‘s full profile, request access.

Request a free trial

OSE Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immu
Biotechnology
Nantes, France
61 As of 2021
000.00
000000000 000.00

000000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cil
0000000000000
Plymouth Meeting, PA
000 As of 0000
000.00
00000000 000.00

000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OSE Immunotherapeutics Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000000 Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
00000000 Formerly VC-backed San Carlos, CA 00 00000 000000000 00000
00000 000000000000 Venture Capital-Backed Hamburg, Germany 00 000.00 00000000000 000.00
You’re viewing 5 of 60 competitors. Get the full list »

OSE Immunotherapeutics Patents

OSE Immunotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020406083-A1 Bifunctional molecules comprising an il-7 variant Pending 17-Dec-2019 00000000000
CA-3159555-A1 Bifunctional molecules comprising an il-7 variant Pending 17-Dec-2019 00000000000
EP-4077364-A1 Bifunctional molecules comprising an il-7 variant Pending 17-Dec-2019 00000000000
CA-3159155-A1 Anti-clec-1a antibodies and antigen-binding fragment thereof Pending 05-Dec-2019 00000000000
EP-4069372-A1 Anti-clec-1a antibodies and antigen-binding fragment thereof Pending 05-Dec-2019 C07K16/2851
To view OSE Immunotherapeutics’s complete patent history, request access »

OSE Immunotherapeutics Executive Team (9)

Name Title Board Seat Contact Info
Dominique Costantini Ph.D Chief Executive Officer & Chairman
Anne-Laure Autret-Cornet Chief Financial Officer & Finance & Administrative Director
Nicolas Poirier Ph.D Chief Scientific Officer & Board Member
Linda Lebon Chief Regulatory Officer
Laurence Schoulepnikoff Director Of operations& Chief Business Officer
You’re viewing 5 of 9 executive team members. Get the full list »

OSE Immunotherapeutics Board Members (12)

Name Representing Role Since
000000000 0000000 Self Board Member 000 0000
00000000 00é00 00. Self Board Member 000 0000
000000 0000 OSE Immunotherapeutics Board Member 000 0000
000000000 00000000 OSE Immunotherapeutics Chief Executive Officer & Chairman 000 0000
0000 00000000 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

OSE Immunotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OSE Immunotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore OSE Immunotherapeutics‘s full profile, request access.

Request a free trial

OSE Immunotherapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 24-Feb-2016 0000000000 000.00 Pharmaceuticals 000000000
To view OSE Immunotherapeutics’s complete acquisitions history, request access »